BriaCell publishes investor presentation on Bria-IMT immunotherapy program for metastatic breast cancer

Reuters2026/07/21 15:28

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Briacell highlighted its lead breast cancer immunotherapy Bria-IMT, with a pivotal Phase 3 study underway in metastatic breast cancer.
Phase 2 combination data showed median PFS 3.6 months for the selected Phase 3 formulation; overall survival 13.3 months for the Phase 3 sequence.
A subset using the Phase 3 formulation and sequence reported median overall survival of 16.6 months in a randomized Phase 2 analysis.
Company cited a 71% intracranial objective response rate in evaluable patients with brain metastases, based on 5 responses in 7 patients.
Next-generation Bria-OTS and Bria-OTS+ programs remain in early-stage breast cancer studies, with prostate and breast candidates slated to enter the clinic in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BriaCell publishes investor presentation on Bria-IMT immunotherapy program for metastatic breast cancer

You may also like

Crypto prices